1. Top
  2. NEWS

RaQualia Pharma and SOCIUM Sign Joint Research Agreement for Discovering The Orphan Indication for Compound by Using AI Technology.

SOCIUM Inc. (Head office: Chuo-ku, Tokyo, CEO: Dr. Hiroshi Kawai; “SOCIUM”) and RaQualia Pharma Inc. (Head Office: Nagoya, Aichi; President & CEO: Mr. Hirobumi Takeuchi; “RaQualia Pharma”) announced that they have entered into a joint research agreement for discovering orphan indications for RaQualia Pharma’s specific compound by using SOCIUM’s AI platforms.

Click here for details (PDF).